A developmental drug company announced it had obtained Food & Drug Administration approval for an investigational new drug application on July 24, 2013.  It’s a Phase I study to test the maximum tolerated dose as administered by injection into the liver.  But over a year later and the drug company has yet to enroll a single patient. [PrescienceLabs.com]

Laboratory researchers and clinical investigators continue to refer to 3-bromopyruvate (3-BP) as new.  But it is an old molecule that had been overlooked until a Korean-born researcher, Young Hee Ko, conducting research at Johns Hopkins University School of Medicine, demonstrated it eradicated advanced-stage liver cancer in animals without side effect.  3-BP simply zapped the energy out of cancer cells (but not healthy cells) and caused them to die in place.

What was remarkable is that not a single cancer cell remained and all of the animals survived to live prolonged cancer-free lives.  The dramatic photographic evidence can be viewed online. [Biochemical & Biophysical Research Communications Sept 2004]